Accumulation of amyloid-β (Aβ) peptides and amyloid plaque deposition in brain is postulated as a cause of Alzheimer’s disease (AD). The precise pathological species of Aβ remains elusive although evidence suggests soluble oligomers may be primarily responsible for neurotoxicity. Crenezumab is a humanized anti-Aβ monoclonal IgG4 that binds multiple forms of Aβ, with higher affinity for aggregated forms, and that blocks Aβ aggregation, and promotes disaggregation. To understand the structural basis for this binding profile and activity, we determined the crystal structure of crenezumab in complex with Aβ. The structure reveals a sequential epitope and conformational requirements for epitope recognition, which include a subtle but critical element that is likely the basis for crenezumab’s versatile binding profile. We find interactions consistent with high affinity for multiple forms of Aβ, particularly oligomers. Of note, crenezumab also sequesters the hydrophobic core of Aβ and breaks an essential salt-bridge characteristic of the β-hairpin conformation, eliminating features characteristic of the basic organization in Aβ oligomers and fibrils, and explains crenezumab’s inhibition of aggregation and promotion of disaggregation. These insights highlight crenezumab’s unique mechanism of action, particularly regarding Aβ oligomers, and provide a strong rationale for the evaluation of crenezumab as a potential AD therapy.
Alzheimer’s disease (AD) is the most common form of dementia, affecting an estimated 5.3 million individuals in the United States and 46.8 million people worldwide1,2. The deposition of extracellular insoluble amyloid plaques composed primarily of amyloid-β (Aβ) peptides in the brain is a hallmark pathologic finding in AD3. An imbalance in the production and/or clearance of Aβ in brain leads to amyloid accumulation and is causally associated with AD pathogenesis4. The accumulation and aggregation of Aβ peptides in brain takes many forms in addition to plaques, including soluble monomers and oligomers, and insoluble fibrils, with a large range of molecular weights from 10 to 1,000 KDa (see review ref. 5). In vitro and ex vivo evidence suggests that soluble oligomers, i.e. “toxic Aβ oligomers,” may be primarily responsible for neurotoxicity6,7,8. Neutralization of toxic Aβ peptides (in its multiple forms) by anti-Aβ monoclonal antibodies is being pursued as therapies for AD, as growing evidence suggests passive immunization against Aβ can provide clinical benefit and perhaps AD prevention9.
Crenezumab is a fully humanized immunoglobulin isotype G4 (IgG4) anti-Aβ monoclonal antibody designed to bind multiple forms of Aβ (monomers, oligomers, fibrils and plaques). In vitro studies demonstrated crenezumab’s ability to block Aβ aggregation, promote Aβ disaggregation of oligomers, and protect neurons from oligomer-induced cytotoxicity10. This broad binding profile and novel mechanism of action, particularly regarding Aβ oligomers, suggest a potential for therapeutic efficacy. Crenezumab’s IgG4 backbone confers reduced activation of FcγRs in comparison to IgG1 and was shown to minimize FcγR-mediated inflammatory activation of microglia – which has also been proposed to contribute to neurotoxicity11,12 – while preserving FcγR-mediated microglial phagocytosis of oligomers10. In recent AD clinical trials involving monoclonal antibodies that bind aggregated forms of Aβ with IgG1 backbones that have fully preserved FcγR-mediated effector function, amyloid-related imaging abnormalities (ARIA) suggestive of vasogenic edema or effusions (ARIA-E) and microhemorrhage (ARIA-H) have been reported13. Crenezumab was designed as an IgG4 based on the hypothesis that an antibody with reduced effector function would have a lower risk of inducing ARIA-E/H and potentially provide a safety advantage over monoclonal antibodies that bind aggregated forms of Aβ with IgG1 backbones14. No increase in ARIA-E was observed with crenezumab in a Phase I study following either a single dose (0.3–10 mg/kg IV) or multiple (four) ascending weekly doses (0.5–5 mg/kg IV)10,15.
A number of monoclonal anti-Aβ antibodies have been tested in clinical studies (see review ref. 16). These antibodies target one or more of three classes of epitope; (1) aducanumab17, bapineuzumab18 and GSK93377619 recognize the N-terminus of Aβ; (2) solanezumab20 and crenezumab10 recognize the mid-region of Aβ; (3) ponezumab21 recognizes the C-terminus of Aβ. Gantenerumab22 recognizes an epitope that includes both amino acids from the N-terminus and mid-region. These antibodies display diverse preferences in engaging Aβ aggregates. Aducanumab and gantenerumab bind primarily to aggregated Aβ, whereas solanezumab is selective for soluble monomers. In contrast, bapineuzumab and crenezumab bind with high affinity to oligomeric forms. Coarse epitope classification of the antibodies does not correlate with their binding profiles. Not surprisingly, high-resolution X-ray crystal structures of antibody/Aβ complexes reported in recent years have revealed diverse epitopes21,22,23,24,25. It is also important to understand the Aβ peptide structure, especially in aggregates, where Aβ oligomerization can produce various products26,27,28,29,30. The basic building block appears to be a single Aβ peptide folded into a U-shaped hairpin-like structure. Hydrophobic residues, including Phe19 and Phe20 and Ile34, bring two strands together and a salt-bridge between residues Asp23 and Lys28 stabilizes the hairpin bend28,31,32,33,34,35 and consequently promotes nucleation of oligomers36. Murakami et al. reported a conformation-specific antibody (11A1) recognizing the hairpin bend structure around Glu22/Asp23 and binding to low-molecular weight oligomers37.
To our knowledge, crenezumab remains the only antibody that targets the mid-region of Aβ peptide and binds to multiple aggregated forms with dissociating effects. To gain insight into this ability, we performed an X-ray crystallographic study on the antibody/Aβ complex. In this report, we describe the structural result and follow up with nuclear magnetic resonance (NMR), mutagenesis and electron microscopy (EM) studies it inspired. Our results provide a precise molecular portrait and uncover critical elements giving rise to the unique functional modality.
Crenezumab captures Aβ peptide in an extended conformation
The antigen-binding fragment (Fab) of crenezumab (CreneFab) was over expressed in E. coli. Co-crystallization of CreneFab with full length Aβ peptide was attempted but hindered due to the low solubility of Aβ peptides. Both Aβ1–42 and Aβ1–40 heavily precipitated in the aqueous environment conducive for Fab crystallization. We then examined a variety of epitope-containing10 fragments of Aβ peptide in co-crystallization trials. The truncated peptides generally showed improved solubility. The fragment with residues 11–25 yielded crystals diffracting to 2.3 Å resolution. For comparison, we also determined the crystal structure of CreneFab alone at 2.5 Å resolution.
Crenezumab binds to a consecutive stretch of twelve Aβ11–25 peptide residues in an extended conformation (Fig. 1A). Aβ residues His13Aβ–Val24Aβ adopt a well-defined structure, while the flanking residues on the N- and C-termini of the peptide are disordered as indicated by poor electron density. The crystallography epitope, therefore, comprises residues 13 through 24, which is consistent with previous epitope mapping results using enzyme-linked immunosorbent assay (ELISA) by Adolfsson et al.10. We further confirmed the ELISA epitope in this work using Ala or Gly substitutions shown in Figure S1.
The complementarity determining regions (CDRs) of crenezumab feature a very short H3 loop of 3 residues and a long L1 loop of 16 residues, thereby creating a deep paratope groove at the interface between VH and Vκ. The Aβ peptide was engulfed in the groove in the complex structure. Interestingly, superposition of the CreneFab-alone and Aβ complex structures showed no major changes in the CDR structure. The root mean square deviation (RMSD) of Cα atoms for the variable domains and CDRs-only was 0.73 Å and 0.71 Å, respectively (Fig. 1B). More pronounced changes were observed in CDR residues Tyr23HC, Asn52HC and Asp101HC, which adopted alternative side chain rotamers upon Aβ binding.
The Aβ peptide made extensive interactions with CreneFab, burying 773 Å2 of surface area on the antibody, most of which involved CDR residues. The shape complementarity score, Sc38, of 0.74 is consistent with tight binding. We tested this empirically by measuring the crenezumab binding affinity to Aβ using surface plasmon resonance (SPR). As described in the methods section, it was technically challenging to control and maintain the density of immobilized Aβ on SPR chips. To generate monomer Aβ chips, we used fragments of Aβ peptide that encompass the epitope and are more soluble. We tested a variety of Aβ fragments with different N- and C-termini and observed similar affinity to crenezumab. The experimental variation resulted in a range of affinity values, which are considered to be equal within a reasonable margin. Figure S2 shows representative sensorgrams. The full-length IgG4 exhibited a KD in range of 3.0–5.0 nM to Aβ monomers and 0.4–0.6 nM to Aβ oligomers, consistent with the structural prediction for high affinity interactions. The aromatic side chains of Phe19Aβ and Phe20Aβ formed a π-π stacking network comprised of one “face-to-face” and two “face-to-edge” interactions with light chain residues Trp96LC and His34LC (Fig. 1C). This π-π stacking network anchored the Aβ peptide to the bottom of the paratope groove. Toward the C-terminal end of the Aβ epitope, two negatively charged residues, Glu22Aβ and Asp23Aβ, engaged in hydrogen bonds with Ser52aHC and Gly33HC, while Glu22Aβ was also linked to CDRs H1, H2, and L3 through a cluster of five structural waters (Fig. 1D). Another major site of interaction was around Lys16Aβ and involved CDR H1 and H3 loops (Fig. 1E). This region of the antibody underwent relatively large structural changes upon Aβ binding, where the Tyr32HC hydroxyl group shifted by ~3 Å, and Asp101HC adopted an alternative rotamer conformation. The positive charge associated with Lys16Aβ was neutralized by Asp101HC as both side chains were sequestered at the binding interface and shielded away from bulk solvent. In addition, Lys16Aβ formed a cation-π interaction with Tyr32HC.
We observed a non-canonical antibody-antigen interaction between Aβ and the N-terminus of the heavy chain (Fig. 1F). The His14Aβ side chain formed a hydrogen bond with the terminal amino group of Glu1HC. An unprotonated state for His14Aβ was implicit in this interaction and was consistent with the basic pH of crystallization (pH 8.5). In addition, the main chain carbonyl oxygen atom of His14Aβ accepted a hydrogen bond from the peptide NH of Val2HC. This interaction appeared further enhanced by a water mediated interaction between His13Aβ and Ser56 LC.
Solution NMR analysis with Aβ1–42 confirms the X-ray epitope
NMR (nuclear magnetic resonance) is a sensitive method for detection of macromolecular interactions. The 2D 1H/15N HSQC spectra39 of isotopically labeled Aβ1–42 are well resolved and have been previously assigned40. To confirm the crystallographic observations obtained with a fragment of Aβ peptide, we carried out solution NMR analysis on Aβ1–42 in the presence and absence of CreneFab. The 15N labeled Aβ1–42 peptide was solubilized into the monomeric state as described in the Methods. The 15N HSQC spectrum in Fig. 2A shows sharp peaks representing the main chain amides, suggesting the sample was free from aggregation at 40 μM. Upon addition of the CreneFab at a 1:1 molar ratio, we observed differential line broadening (disappearance of peaks) in a subset of the peaks, indicating the residues associated with those peaks either directly interact with the antibody or are located in close proximity of the interaction interface. The peaks corresponding to the epitope from residues His13Aβ to Val24Aβ display significant line broadening as quantified in the methods and indicated in Fig. 2B and Figure S3. Four residues (His6Aβ, His14Aβ, Asp23Aβ and Asp27Aβ) displayed low intensities in the uncomplexed spectra and were not analyzed. Residues immediately adjacent in sequence to the epitope (Glu11, Val12, Gly25, Ser26) also displayed perturbation as expected. None of the residues distal in sequence showed significant line broadening. This observation confirms the epitope identified in the crystal structure is also relevant to full-length Aβ in solution.
Mutagenesis study reveals binding contribution from critical residues
We evaluated binding contributions from Fab residues in contact with Aβ by single alanine mutations. The relative binding affinities measured using surface plasmon resonance (SPR) are shown in Fig. 3, where a 2-fold change of affinity relative to wild-type is considered significant. Alanine mutants of Tyr32HC, Gly95HC, or Asp101HC completely abolished binding. As described above, Tyr32HC and Asp101HC comprise the Lys16Aβ binding pocket and neutralize its charge (Fig. 1E). The dramatic loss of affinity suggests a proper binding site for Lys16Aβ is indispensible. Gly95HC, on the other hand, forms the bottom of the groove. An alanine in this position introduces a steric clash with Phe19Aβ and disrupts the π-π stacking network illustrated in Fig. 1C. Most of the light chain mutations strongly reduced, but did not eliminate, binding. Those residues are in the vicinity of the Phe19Aβ/Phe20Aβ binding pocket, including Tyr32LC, His34LC, Lys50LC and Ser91LC. Mutating Ser91LC or His34LC to alanine would disrupt π-π stacking with Phe19Aβ. Tyr32LC and Lys50LC side chains form the rim of the binding grove and make contact with the Aβ peptide. Interestingly, the Ser52aLC to alanine mutation only marginally reduced the affinity by 1.8-fold indicating this hydrogen bond contributed a relatively small portion of the total binding energy and a missing hydroxyl group was well tolerated. However, as presented in the discussion section, this interaction contributes to the recognition of Aβ peptide in an extended conformational state. It is noteworthy that the non-conventional antibody- antigen interaction involving the amino-terminus of the heavy chain also contributes to total binding, as deletion of Glu1HC and Val2HC caused a 2.6-fold reduction of affinity. This interaction defines a more extended epitope and potentially distinguishes Crenezumab from other antibodies targeting the middle region of Aβ.
Electron microscopy showed binding of crenezumab to amyloid fibers
We have described crenezumab’s unique binding properties, and measured the binding affinities to Aβ monomers and oligomers above. To further characterize the binding behavior of crenezumab with Aβ fibrils, we performed immunogold negative-staining transmission electron microscopy (TEM). We first incubated crenezumab with Aβ1–42 fibrils on TEM grids and then labeled the bound crenezumab with a secondary biotinylated antibody, which was subsequently detected with streptavidin conjugated with 10 nm colloidal gold particles (Fig. 4).
By TEM analysis we observed numerous gold particles associated with tangles of Aβ fibrils, indicating binding of crenezumab to Aβ fibrils (Fig. 4A). In addition we found many gold particles bound to low molecular weight (LMW) Aβ aggregated species presumably including Aβ oligomers and small fragments of Aβ fibrils (Fig. 4B). In contrast, gold particles were not observed in the negative control experiments of Aβ fibrils incubated with an unrelated anti-gD antibody (Fig. 4C), confirming that crenezumab bound specifically to Aβ fibrils and to LMW Aβ. In another negative control experiment, we exposed empty TEM grids to crenezumab and all other secondary immunogold reagents and observed no labeling, ruling out the possibility of crenezumab nonspecifically sticking to the grid surface (Fig. 4D). We then quantified the immunogold labeling density by calculating the average number of gold particles per um2 area in twenty randomly selected regions in the EM graph. As shown in Fig. 4E, the Aβ fibrils exhibited 7-fold higher labeling density comparing to LMW Aβ, although the same concentration of crenezumab was used for binding in both experiments. The negative control experiments showed near-zero density as expected.
Closer inspection of crenezumab labeled Aβ fibrils revealed a non-uniform distribution of the antibody along the long axis of fibrils (Fig. 4A). This phenomenon suggests that crenezumab is more likely to bind in regions of massive tangling, bending or crisscrossing. We reason that the irregularities in the filament structures may have increased the probability of unfolding individual Aβ hair-pins and consequently exposed the epitopes for crenezumab. Taken together, our TEM studies showed crenezumab binds to specific regions of Aβ fibrils.
The crystal structure of CreneFab with Aβ11–25 reveals a well-defined contiguous epitope His13Aβ–Val24Aβ in an extended conformation. This region is consistent with the earlier observation by Adolfsson and colleagues10. Complete burial of Lys16 and Phe19-Phe20 anchors the Aβ peptide into the CDR groove and explains the high binding affinity. Remarkably, the details of antibody binding seem to hinder Aβ aggregation and promote disaggregation in two ways. First, the antibody occludes half of the “hydrophobic core” sequence responsible for self-association and oligomerization5, residues Leu17Aβ–Ala21Aβ. Second, the hairpin turn is disrupted. It has been shown that a salt-bridge between Asp23Aβ and Lys28Aβ stabilizes the hairpin bend in Aβ self-assembly28,36,41. In our structure, the Asp23Aβ side chain forms hydrogen bonds with Gly33HC and Ser52aHC. Hence, sequestration of Asp23Aβ presents a hindrance to aggregation. The important role of Asp23Aβ in crenezumab interaction explains the significant loss of binding associated with the Asp23AlaAβ mutation (Figure S1). Glu22Aβ has also been implicated in disease37. A water mediated H-bond network between Glu22Aβ and crenezumab provide additional hindrance to aggregation (Fig. 1D). Additionally, crenezumab is distinct from those antibodies that recognize a specific Glu22Aβ/Asp23Aβ turn conformation37, as the crenezumab complex shows no β-turn for these residues.
We measured crenezumab affinities for Aβ monomers and soluble aggregates using a series of single-cycle kinetics titration experiments. The advantage of this method is that it avoids harsh regeneration conditions, which we found to degrade the immobilized Aβ aggregates (data not shown). The soluble aggregates we generated comprised multiple soluble oligomeric species. Data in Figure S2 is therefore a measurement of crenezumab affinity for a heterogeneous population of oligomers. The results are largely consistent, i.e. in the same concentration range, with previously published ELISA results10; however, SPR showed a more pronounced affinity distinction in crenezumab affinity for Aβ monomer versus oligomers. The difference in the results from these assay formats is likely a reflection of their different sensitivities to avidity.
Crenezumab and solanezumab both target epitopes in the middle region of Aβ. Despite certain sequence homology in their respective CDRs (Figure S4), they exhibited vastly different specificity for various oligomeric forms of Aβ. This long-standing puzzle was unresolved even after examining the published crystal structure of the solanezumab/Aβ complex25. Here, we present a key finding by comparing the two structures. Crenezumab and solanezumab actually target slightly different epitopes, His13Aβ–Val24Aβ versus Lys16Aβ–Ser26Aβ, respectively. While bound to solanezumab, residues Ala21Aβ–Ser26Aβ adopt an α-helical secondary structure and residues Ala21Aβ–Asp23Aβ make multiple hydrogen bonds and van der Waals contacts with the antibody. Specifically, Asp23Aβ forms two hydrogen bonds with the Ser33HC_solan side chain (Oγ) and main chain (NH) which require that solanezumab binds the α-helical structure. In contrast, crenezumab bound Aβ peptide adopts a random coil structure in the section comprising residues Ala21Aβ through Val24Aβ, and is disordered beyond Val24Aβ. In the crenezumab complex, residue Asp23Aβ forms a hydrogen bond with the antibody heavy chain residue at position (Gly33HC_crene main chain (NH)) but Glycine offers no side chain for a hydrogen bond like that of the solanezumab Ser33HC_solan. Instead, Asp23Aβ forms a unique hydrogen bond with Ser52aHC_crene sidechain (Oγ). This relatively subtle change in the H-bonding pattern supports binding to a more open conformation of Aβ. Comparing the two complexes, the largest Aβ side chain difference is found in Glu22Aβ. In binding to crenezumab, Glu22Aβ plunges into a volume surrounded by CDRs H1, H2, L3 and a water cluster. In contrast, the counterpart region in solanezumab is blocked by side chains of Ser33HC_solan and Gln50HC_solan, and there are no significant interactions between Glu22Aβ and solanezumab (Fig. 5). On the other hand, at the N-terminal Aβ segment, His13Aβ and His14Aβ make direct interactions with the N-terminus of the CreneFab heavy chain and contribute to the overall binding energy as demonstrated by SPR. We conclude that crenezumab recognizes a non-helical epitope that is shifted by two residues toward the Aβ N-terminus relative to the solanezumab epitope. Only monomeric Aβ peptides have been shown to adopt α-helical structure by solution NMR42, albeit in the presence of helix promoting agents such as HFIP or SDS. We propose that the α-helical epitope is present in a subpopulation of monomeric Aβ but is absent in oligomers and higher order aggregates. This provides a plausible reason for solanezumab’s preference for soluble Aβ monomers20. Conversely, crenezumab recognizes an epitope in a more extended conformation, which is probably available in a wider variety of Aβ species, including oligomers.
The present studies shed light on the mechanism of action for crenezumab and collectively enhance our understanding of the mechanism behind the various anti-Aβ antibodies currently under clinical investigation. A central question remains for AD therapeutic drug development – what is the nature of target engagement that leads to maximal efficacy in the clinic? Crenezumab is unique in its recognition of a sequence motif and conformation of Aβ that is apparently more broadly available in different aggregation states. Crenezumab buries half of the hydrophobic core and neutralizes the salt-bridge responsible for self-association and thereby destabilizes the β-hairpin, the building block for all forms of Aβ oligomers and fibrils known to date. These characteristics provide a strong rationale for the evaluation of crenezumab as novel potential therapy for AD.
Cloning, expression and purification of Crenezumab Fab
Protease treatment of intact crenezumab produced Fab fragment in low yield, which failed to crystallize. Successful crystallization employed a mutated version of the Crenezumab Fab (CreneFab). It contains the unaltered light chain, one mutation in the VH domain, T108L, and 8 mutations in the CH1 domain. All these mutations are remote from the CDRs and are unlikely to have influenced the structure. To produce CreneFab in E. coli, the variable sequences for the light and heavy chain Fab were amplified by PCR using overlapping oligos designed for restriction independent cloning. The product was sub-cloned into E. coli expression plasmid AEP1 and transformed into expression strain 24B4. The resulting Fab protein was secreted into the periplasm. The E. coli cell pellet was lysed using a cell disrupter (Microfluidics) and the lysate clarified by centrifugation. The Fab was purified from the supernatant by standard protein G column affinity techniques, cation exchange chromatography using SP sepharose, and finally size exclusion chromatography using a Superdex 75 16/60 column. The final protein buffer was 0.15 M NaCl, 20 mM Tris pH 7.5.
Antibody affinity measurement by Surface Plasmon Resonance (SPR)
A BIAcoreTM T200 instrument was used to determine the binding affinity of anti-Aβ Fab by single-cycle kinetics, SPR measurement with Aβ peptides. Briefly, series S sensor chip CM5 was activated with 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimidehydrochloride (EDC) and N-Hydroxysuccinimide (NHS) reagents according to the supplier’s instructions, and streptavidin (Pierce) was coupled to achieve approximately 2000 response units (RU), followed by blocking un-reacted groups with 1 M ethanolamine.
For kinetics measurements, biotinylated Aβ (11–28 or oligomeric 1–42) was first injected at 10 μL/min flow rate into 3 different flow cells (FC) to reach approximately 100–200 RU, except for FC1 (reference). 5-fold serial dilutions of monomeric Fab in HBS-P buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% surfactant P20) from low (0.8 nM) to high (500 nM) were sequentially injected as analyte (flow rate: 30 μL/min) in one cycle with no regeneration between injections. It is difficult to control the density of immobilized Aβ on SPR chips. A kinetic titration series was employed in order to avoid harsh regeneration conditions, which were found to be detrimental to immobilized Aβ aggregates. The sensorgram was recorded and subject to reference and buffer subtraction before evaluation by BIAcoreTM T200 Evaluation Software (version 2.0). The association rates (kon) and dissociation rates (koff) were calculated using a simple one-to-one Langmuir binding model. The equilibrium dissociation constant (KD) was calculated as the ratio koff/kon.
Generation and Isolation of Aβ Aggregates
Aβ aggregates were prepared from biotinylated synthetic Aβ(1–42) peptides (AnaSpec, Fremont, CA) and initially disaggregated by dissolution in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP), followed by evaporation under a stream of nitrogen. The peptide film was thoroughly dissolved in 10 mM NaOH, neutralized in an equal volume of 100 mM sodium phosphate buffer, pH 7.4. UV absorbance of the solution at 280 nm was measured, the peptide concentration determined using the respective theoretical extinction coefficient and adjusted by dilution to 1.0 mg/ml with 5 mM NaOH, 50 mM sodium phosphate buffer, pH 7.4.
To generate fibrils for immunogold electron microscopy and soluble, prefibrillar aggregates (oligomers) for affinity determinations, the above material was incubated at 37 °C for ≥48 hours. Insoluble fibrils were removed with a 0.2-μm syringe filter and the filtrate was fractionated by size exclusion chromatography (Superdex 200, GE Healthcare) in a mobile phase of PBS, to isolate soluble aggregate from any remaining monomeric Aβ.
NMR analysis of antibody Aβ1–42 interaction
All NMR spectra were recorded on a Bruker Avance III 800 MHz spectrometer using a TXI cryo-probe. The samples consisted of 180 μL of a 40 μM 13C/15N labeled Aβ1–42 (R-Peptide, Georgia) solution prepared from NaOH- treated stocks as described by the vendor. The final buffer was 20 mM NaPO4 buffer set to a pH of 7.0. CreneFab was added to a 1:1 ratio in the same buffer. The samples were measured in 3 mm NMR tubes (Norell, North Carolina) at the calibrated temperature of 300 K. 2D 1H/15N HSQC spectra were recorded with 2048 data points in the proton dimension and 256 data points in the 15N dimension with a total measuring time of 9 hours. All data were processed in TopSpin (Bruker, Karlsruhe) with 4096 data points in the proton and 2048 data points in the 15N dimension using forward maximum entropy linear prediction. Due to sample instability, only spectra of peptide alone and in a 1:1 complex with CreneFab were recorded. The 1H/15N correlated spectra were assigned using the BMRB data base values from submission BMRB-ID 17793 and comparison with published NMR data. Data analysis and visualization was done using CCPN (http://www.ccpn.ac.uk/about). Residues belonging to the binding epitope were identified by signal intensity attenuation and those residues with intensities below the noise mapped to the epitope.
Immunogold negative staining TEM micrographs of crenezumab binding to Aβ fibrils
Aβ was used after 48 hours of reconstitution (in 5 mM NaOH, 50 mM sodium phosphate buffer, pH 7.4). Formvar and carbon coated TEM grids were incubated for 15 minutes at room temperature with a suspension of reconstituted Aβ fibrils and then blocked for 30 minutes in EM blocking medium for gold conjugates (Aurion) to prevent unspecific sticking of antibodies to the grid surface. The grids were then incubated with crenezumab or anti-gD antibody (negative control) for 45 minutes; all antibodies were diluted 1/200 (final concentration was 5 ug/ml) in EM blocking medium. After washing in PBS the grids were incubated with a donkey anti-human IgG biotinylated secondary antibody (Jackson Immunoresearch; diluted 1/200) for 30 minutes. The grids were then washed in PBS and incubated with a streptavidin-colloidal gold (10 nm) conjugate (British Biocell International) diluted at 1/20 in EM blocking medium for 30 minutes. Finally the grids were washed in PBS, rinsed in distilled water and negatively stained with Nano-W (Nanoprobes) for 60 seconds. The specimens were air dried and then examined in a JEOL JEM1400 TEM at 80 kV. Digital images were captured with a GATAN Ultrascan 1000 CCD camera.
For quantification of gold labeling densities twenty randomly selected areas of each sample were imaged at 20000× and the average number of gold particles +/− standard deviation per 1 um2 area was calculated.
Crystallization, diffraction data collection and structure determination
High throughput crystallization screenings were set up using a Phoenix crystallization robot (Art Robbins, Mountain View, CA) in 96-well format. Optimized apo CreneFab crystals grew as large blocks at 20 °C from hanging-drop vapor diffusion experiments in Linbro plates. The crystallization drops contained equal volumes of protein and reservoir solutions. The final reservoir condition contained 2.4 M ammonium sulfate, 0.1 M HEPES pH 7.5. The apo crystals were preserved for data collection by brief soaking in a cryo-buffer (25% glycerol added to the reservoir solution), followed by sudden immersion into liquid nitrogen.
Complexes of CreneFab and several peptides (Aβ residues 1–42, 15–36, 1–28, 1–16, 11–25, ANASPEC, EGT Group) were produced by mixing solutions of 15 mg of purified Fab and 1 mg of peptide. The best crystals came from the peptide 11–25. Rod-shaped crystals were obtained at 4 °C in Hampton Crystal Screen HT condition A6, which contains 0.2 M magnesium chloride hexahydrate, 0.1 M Tris hydrochloride pH 8.5 and 30% w/v polyethylene glycol 4000. The sitting-drop vapor diffusion experiments were setup using the Phoenix crystallization robot in volumes of 0.5 μL protein sample plus 0.5 μL reservoir solution. The crystals were preserved by soaking into cryo-buffer (30% PEG3350, 0.2 M MgSO4, 0.1 M Tris pH 8.5) followed by sudden immersion into liquid nitrogen.
X-ray diffraction data collection and structure determination
The diffraction data of CreneFab and CreneFab/Aβ complex crystals were collected using monochromatic X-rays at the Stanford Synchrotron Radiation Lightsource (SSRL) beam line 9-2 (MAR325 CCD detector) and beam line 11-1 (Pilatus-6M detector), respectively. In both cases, the rotation method was applied to a single crystal for the complete data set. Data reduction was done using program HKL200043 for CreneFab data, and mosflm and the CCP4 program suite for CreneFab/Aβ complex. Data reduction statistics are shown in Table S1.
The apo CreneFab structure was solved by molecular replacement (MR) using program Phaser44. A previously determined Fab structure (PDB: 3R1G, ref. 45) was used as the search model. In order to compensate for possible elbow angle differences, we searched VH/VL and CH1/CL domains separately. Two CreneFab molecules were found in the crystallographic asymmetric unit. Structure refinement was done through iterative manual rebuilding in graphics program COOT46 and least-square minimization calculation using programs REFMAC547 and PHENIX48. TLS treatment of atomic thermal factors was applied. Several small buffer molecules are identified and built into the final refined structure. Similarly, the CreneFab/Aβ complex structure was determined by MR, using apo CreneFab structure as the search model. There is one molecular complex in the asymmetric unit, and the initial difference map (Fo-Fc) clearly indicated Aβ binding to the antibody. The structure was then refined as for the apo structure. The final refinement statistics are shown in Table S1.
Accession codes: The crystal structures of creneFab and crenFab/Aβ complex are deposited into the Protein Data Bank, accession code 5KMV and 5KNA respectively.
How to cite this article: Ultsch, M. et al. Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin. Sci. Rep. 6, 39374; doi: 10.1038/srep39374 (2016).
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Alzheimer’s Association . 2015 Alzheimer’s disease facts and figures. Alzheimers Dement 11, 332–384 (2015).
Price, M. et al. World Alzheimer report 2015: the global impact of dementia. Alzheimer’s Disease International (2015).
Selkoe, D. J., Abraham, C. R., Podlisny, M. B. & Duffy, L. K. Isolation of low-molecular-weight proteins from amyloid plaque fibers in Alzheimer’s disease. J Neurochem 46, 1820–1834 (1986).
Walsh, D. M. et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535–539 (2002).
Murakami, K. Conformation-specific antibodies to target amyloid beta oligomers and their application to immunotherapy for Alzheimer’s disease. Biosci Biotechnol Biochem 78, 1293–1305 (2014).
Haass, C. & Selkoe, D. J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nature reviews. Molecular cell biology 8, 101–112 (2007).
Wang, Z. X., Tan, L., Liu, J. & Yu, J. T. The Essential Role of Soluble Abeta Oligomers in Alzheimer’s Disease. Molecular neurobiology 53, 1905–1924 (2016).
Benilova, I., Karran, E. & De Strooper, B. The toxic Abeta oligomer and Alzheimer’s disease: an emperor in need of clothes. Nature neuroscience 15, 349–357 (2012).
Sperling, R. A. et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med 6, 228fs213 (2014).
Adolfsson, O. et al. An effector-reduced anti-beta-amyloid antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta. J Neurosci 32, 9677–9689 (2012).
Heneka, M. T. et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol 14, 388–405 (2015).
Xing, B., Bachstetter, A. D. & Van Eldik, L. J. Microglial p38alpha MAPK is critical for LPS-induced neuron degeneration, through a mechanism involving TNFalpha. Mol Neurodegener 6, 84 (2011).
Fuller, J. P., Stavenhagen, J. B. & Teeling, J. L. New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer’s Disease. Front Neurosci 8, 235 (2014).
Wilcock, D. M. et al. Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci 26, 5340–5346 (2006).
Cummings, J. C. W. et al. A randomized, double-blind, placebo-controlled phase 2 study to evaluate the efficacy and safety of crenezumab in patients with mild to moderate Alzheimer’s disease. Alzheimer’s Dementia 10 (2014).
Moreth, J., Mavoungou, C. & Schindowski, K. Passive anti-amyloid immunotherapy in Alzheimer’s disease: What are the most promising targets? Immun & Ageing 10, 18 (2013).
Bussiere, T. et al. inventors; Biogen Idec International Neuroscience Gmbh, assignee. A Method Of Reducing Brain Amyloid Plaques Using Anti-Aβ Antibodies. Uniuted States patent application WO2014089500 A1. 2014 Jun 12.
Schenk, D. B. B. CA. Passive immunization treatment of Alzheimer’s disease. United States patent (2004).
Leyhe, T. et al. Modulation of beta-amyloid by a single dose of GSK933776 in patients with mild Alzheimer’s disease: a phase I study. Alzheimers Res Ther 6, 19 (2014).
Holtzman, D. M. et al. Humanized Antibodies That Sequester Amyloid Beta Peptide. Uniuted States patent US 8338120. 2002 Dec 25.
La Porte, S. L. et al. Structural basis of C-terminal beta-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer’s disease. J Mol Biol 421, 525–536 (2012).
Bohrmann, B. et al. Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J Alzheimers Dis 28, 49–69 (2012).
Miles, L. A. et al. Amyloid-beta-anti-amyloid-beta complex structure reveals an extended conformation in the immunodominant B-cell epitope. J Mol Biol 377, 181–192 (2008).
Miles, L. A., Crespi, G. A., Doughty, L. & Parker, M. W. Bapineuzumab captures the N-terminus of the Alzheimer’s disease amyloid-beta peptide in a helical conformation. Sci Rep 3, 1302 (2013).
Crespi, G. A., Hermans, S. J., Parker, M. W. & Miles, L. A. Molecular basis for mid-region amyloid-beta capture by leading Alzheimer’s disease immunotherapies. Sci Rep 5, 9649 (2015).
Eanes, E. D. & Glenner, G. G. X-ray diffraction studies on amyloid filaments. J Histochem Cytochem 16, 673–677 (1968).
Kirschner, D. A., Abraham, C. & Selkoe, D. J. X-ray diffraction from intraneuronal paired helical filaments and extraneuronal amyloid fibers in Alzheimer disease indicates cross-beta conformation. Proc Natl Acad Sci USA 83, 503–507 (1986).
Petkova, A. T. et al. A structural model for Alzheimer’s beta -amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci USA 99, 16742–16747 (2002).
Luhrs, T. et al. 3D structure of Alzheimer’s amyloid-beta(1–42) fibrils. Proc Natl Acad Sci USA 102, 17342–17347 (2005).
Paravastu, A. K., Leapman, R. D., Yau, W. M. & Tycko, R. Molecular structural basis for polymorphism in Alzheimer’s beta-amyloid fibrils. Proc Natl Acad Sci USA 105, 18349–18354 (2008).
Gu, L. et al. Antiparallel triple-strand architecture for prefibrillar Abeta42 oligomers. J Biol Chem 289, 27300–27313 (2014).
Xiao, Y. et al. Abeta(1–42) fibril structure illuminates self-recognition and replication of amyloid in Alzheimer’s disease. Nat Struct Mol Biol 22, 499–505 (2015).
Tycko, R. Alzheimer’s disease: Structure of aggregates revealed. Nature 537, 492–493 (2016).
Walti, M. A. et al. Atomic-resolution structure of a disease-relevant Abeta(1-42) amyloid fibril. Proc Natl Acad Sci USA 113, E4976–4984 (2016).
Colvin, M. T. et al. Atomic Resolution Structure of Monomorphic Abeta42 Amyloid Fibrils. J Am Chem Soc 138, 9663–9674 (2016).
Sciarretta, K. L., Gordon, D. J., Petkova, A. T., Tycko, R. & Meredith, S. C. Abeta40-Lactam(D23/K28) models a conformation highly favorable for nucleation of amyloid. Biochemistry 44, 6003–6014 (2005).
Murakami, K. et al. Monoclonal antibody against the turn of the 42-residue amyloid beta-protein at positions 22 and 23. ACS Chem Neurosci 1, 747–756 (2010).
Lawrence, M. C. & Colman, P. M. Shape complementarity at protein/protein interfaces. J Mol Biol 234, 946–950 (1993).
Kay, L. E., Keifer, P. & Saarinen, T. Pure Absorption Gradient Enhanced Heteronuclear Single Quantum Correlation Spectroscopy with Improved Sensitivity. J Am Chem Soc 114, 10663–10665 (1992).
Fawzi, N. L., Ying, J., Ghirlando, R., Torchia, D. A. & Clore, G. M. Atomic-resolution dynamics on the surface of amyloid-beta protofibrils probed by solution NMR. Nature 480, 268–272 (2011).
Masuda, Y. et al. Identification of physiological and toxic conformations in Abeta42 aggregates. Chembiochem 10, 287–295 (2009).
Tomaselli, S. et al. The alpha-to-beta conformational transition of Alzheimer’s Abeta-(1–42) peptide in aqueous media is reversible: a step by step conformational analysis suggests the location of beta conformation seeding. Chembiochem 7, 257–267 (2006).
Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Macromolecular Crystallography, Pt A 276, 307–326 (1997).
McCoy, A. J. et al. Phaser crystallographic software. J Appl Crystallogr 40, 658–674 (2007).
Atwal, J. K. et al. A therapeutic antibody targeting BACE1 inhibits amyloid-beta production in vivo. Sci Transl Med 3, 84ra43 (2011).
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66, 486–501 (2010).
Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53, 240–255 (1997).
Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66, 213–221 (2010).
We thank the staff at Stanford Synchrotron Light-source (SSRL), Dr. Seth Harris and Dr. Xiaolei Ma for assistance on data collection. Use of the SSRL, SLAC National Accelerator Laboratory, is supported by the U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences under Contract No. DE-AC02-76SF00515.
M.U., B.L., T.M., M.M., T.W.B., M.R., J.A.E., C.E., J.K.A. and W.W. are employees of Genentech. G.F. and R.J.W. were employees of Genentech while engaged in the research project. O.A., A.M., A.P. and M.P. are employees of A.C. Immune S.A.
Electronic supplementary material
About this article
Cite this article
Ultsch, M., Li, B., Maurer, T. et al. Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin. Sci Rep 6, 39374 (2016). https://doi.org/10.1038/srep39374
Evaluating the Multifunctionality of a New Modulator of Zinc-Induced Aβ Aggregation Using a Novel Computational Approach
Journal of Chemical Information and Modeling (2021)
Computational Investigation of Gantenerumab and Crenezumab Recognition of Aβ Fibrils in Alzheimer’s Disease Brain Tissue
ACS Chemical Neuroscience (2020)
Cellular and Molecular Neurobiology (2020)
Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer’s Disease Treated with Escalating Doses for up to 133 Weeks
Journal of Alzheimer's Disease (2020)
Advanced Therapeutics (2020)